Business Context and Reporting Period
Company: Estrella Immunopharma, Inc. (ESLA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Estrella is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. Its lead product candidate, EB103, is a CD19-directed ARTEMIS T-cell therapy currently in the Phase I/II STARLIGHT-1 clinical trial for relapsed/refractory B-cell Non-Hodgkin's Lymphoma. The company relies heavily on Eureka Therapeutics, Inc. (a controlling shareholder) for manufacturing, research, and development services.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2025 | Twelve Months Ended Dec 31, 2024 (Unaudited) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.1) million | $(8.8) million |
| Research & Development Expenses | $10.2 million | $6.4 million |
| General & Administrative Expenses | $2.8 million | $2.4 million |
| Cash and Cash Equivalents (Ending) | $1.4 million | $0.9 million |
| Accumulated Deficit | $(37.0) million | $(23.9) million |
| Net Cash Used in Operating Activities | $(1.8) million | $(3.1) million (6-month transition) |
| Working Capital Deficit | $(11.9) million | N/A |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $4.3 million (49%) compared to the prior twelve-month period, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses rose from $6.4 million to $10.2 million. This increase is attributed to higher service fees from Eureka Therapeutics for the STARLIGHT-1 clinical trial, specifically due to the dosing of seven patients and the activation of a second clinical site in 2025, compared to two patients dosed in the prior period.
- Related Party Liabilities: Accrued liabilities to related parties (Eureka) increased significantly to approximately $12.4 million as of December 31, 2025, reflecting milestone achievements in the clinical trial.
- Financing Activity: The company raised approximately $2.4 million in gross proceeds from a private placement between May and September 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management and the independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. With only $1.4 million in cash and a recurring loss of $13.1 million, management believes current resources are insufficient to meet obligations for the next 12 months without additional financing.
Clinical Progress
- EB103 (STARLIGHT-1): Phase I dose-escalation completed with 9 patients. No treatment-related serious adverse events were reported. The high-dose cohort achieved a 100% complete response rate at Month 1. The trial has advanced to the Phase II expansion phase.
- EB104: Preclinical development continues for this dual-targeting (CD19/CD22) candidate.
Key Risks and Contingencies
- Dependence on Eureka: Estrella relies on Eureka for manufacturing, R&D, and IT. Eureka holds over 50% of voting power, making Estrella a "controlled company."
- Internal Control Weaknesses: The company identified material weaknesses in internal controls over financial reporting due to a lack of qualified full-time accounting personnel.
- Nasdaq Compliance: The company received a notice of non-compliance regarding the failure to hold an annual meeting within the required timeframe. An extension was granted until June 29, 2026.
- Derivative Liabilities: A derivative liability of $356,505 was recorded related to "True-Up Shares" from recent private placements.
Subsequent Events
On January 6, 2026, the company consummated a registered direct offering and concurrent private placement, raising approximately $8.0 million in gross proceeds.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.0 million raised in January 2026 against the $12.4 million accrued liability to Eureka and ongoing burn rate.
- Related Party Agreements: Review the Statement of Work #001 with Eureka to understand the total $33.0 million fee structure and payment triggers for the STARLIGHT-1 trial.
- Internal Controls: Assess the remediation plan for the material weaknesses in financial reporting and the timeline for achieving effective controls.
- Nasdaq Status: Monitor the company's ability to hold the joint 2025/2026 annual meeting by June 29, 2026, to avoid delisting.
- Clinical Data: Await final data from the Phase II expansion of STARLIGHT-1 to validate the preliminary 100% response rate observed in the small Phase I cohort.